Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCD-044 in moderate to severe atopic dermatitis
NCT04684485Phase 2Completed
- Sponsor
- Sun Pharma
- Start
- Jul 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of vibozilimod in atopic dermatitis (AD) (4 arms), sponsored by Sun Pharma. Primary endpoint: ≥75% Improvement in Eczema Area and Severity Index at 16 weeks. Started Jul 2021; status: completed.
02
Drugs
vibozilimod
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04684485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04684485.